Phase 1 Parkinson's Disease Trial, Recruiting NCT07310264 Sponsor: Vertero Therapeutics Condition: Parkinson's Disease
Back to Parkinsons Disease

Phase 1 Parkinson's Disease Trial, Recruiting

NCT07310264
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • A neurologist has confirmed a diagnosis of Parkinson's disease (PD) within the last 10 years before the screening visit.
  • The person has current or past problems with their digestive system moving slowly, or ongoing constipation.
  • The person scores below 3 on a standard scale used to measure how advanced Parkinson's disease symptoms are (the Modified Hoehn and Yahr Scale).
  • In the investigator's opinion, the person is able to swallow multiple large capsules without help or difficulty.
  • The person has been on a stable dose and schedule of any current prescription medications (except certain Parkinson's medications — see exclusions) or supplements for at least 60 days before joining, and is able to keep those medications unchanged during the study.
  • The person has suitable veins that allow blood samples to be taken.

Who may not be able to join:

  • The person has a known allergy or sensitivity to any ingredient in the study drug (VT-5006) or placebo, or has a history of serious allergic reactions or anaphylaxis to any drug, food, or other substance.
  • The person is taking levodopa/carbidopa or levodopa/benserazide but has not been on a stable dose and schedule for at least 21 days before the first study visit (other Parkinson's treatments may be considered on a case-by-case basis by the medical team).
  • The person has a clinically significant abnormal heart rhythm on an ECG, or has a specific heart electrical measurement (corrected QT interval) above 450 ms for males or 470 ms for females.
  • The person has significant abnormalities in blood or urine test results, as assessed by the investigator.
  • The person has certain liver-related blood test results that are too high — specifically, total bilirubin above 1.5 times the normal upper limit, or liver enzyme levels (ALT or AST) more than twice the normal upper limit (a specific exception may apply for a condition called Gilbert's syndrome — confirm with trial site).
  • The person has a history of lower back (lumbar) surgery that, in the investigator's opinion, could interfere with or create risks during a lumbar puncture (spinal tap) procedure.
  • The person has any other medical reason that would make a lumbar puncture unsafe or unsuitable (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 15 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +31 0715246400

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Vertero Therapeutics
Registry
ClinicalTrials.gov
Start date
30 October 2025
Est. completion
28 September 2026

Where this trial is recruiting

🇳🇱 Netherlands

Primary endpoints

Number of participants with treatment-related adverse events (AEs)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov